Skip to main content
SpringerLink
Log in

Management of chronic hepatitis B and C virus infections

  • Symposium on Hepatology-II
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Hepatitis B and C virus (HBV and HCV) infections present an important health problem causing significant morbidity and mortality on a worldwide scale. The younger the subjects infected, the higher the risk predisposing to progression towards chronic infection. Treatment of chronic HBV and HCV infections is aimed at reducing hepatic inflammation and thus improving the symptoms, decreasing the likelihood of long-term sequelae such as hepatocellular carcinoma, and increasing the survival rate. Interferon accelerates the spontaneous course of chronic HBV infection in children with greater disease activity and lower levels of replication. There is limited information on the use of lamivudine and its long-term benefit in children with chronic HBV infection. The response of combination therapy with IFN and ribavirin in children with chronic HCV infection is still under investigation. The long-term clinical and virological effects of various drugs used in chronic HBV and HCV infections on children remain to be evaluated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kane M. Global programme for control of hepatitis B infection.Vaccine 1995; 13: S47–49.

    PubMed  Google Scholar 

  2. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: a global perspective.Vaccine 1999; 17: 1730–1733.

    Article  PubMed  CAS  Google Scholar 

  3. Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia.Gut 1996; 38: S18–23.

    Article  PubMed  Google Scholar 

  4. Canadian consensus conference on the management of viral hepatitis. Canadian Association for the Study of the Liver.Can J Gastroenterol 2000; 14 : 5B–20B.

    Google Scholar 

  5. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan.N Engl J Med 1975; 292: 771–774.

    Article  PubMed  CAS  Google Scholar 

  6. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review.Clin Infect Dis 1995; 20: 992–1000.

    PubMed  CAS  Google Scholar 

  7. Fattovich G, Giustina G, Sanchez-Tapias Jet al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP).Am J Gastroenterol 1998; 93: 896–900.

    Article  PubMed  CAS  Google Scholar 

  8. Knodell RG, Ishak KG, Black WCet al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.Hepatology 1981; 1: 431–435.

    Article  PubMed  CAS  Google Scholar 

  9. Jara P, Bortolotti F. Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus ’advice based on experience in European children.J Pediatr Gastroenterol Nutr 1999; 29: 163–170.

    Article  PubMed  CAS  Google Scholar 

  10. Lin SM, Sheen IS, Chien RN, Chu CM, Iiaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.Hepatology 1999; 29: 971–975.

    Article  PubMed  CAS  Google Scholar 

  11. Bortolotti F, Jara P, Barbera Cet al. Long-term effect of alpha interferon in children with chronic hepatitis B.Gut 2000; 46: 715–718.

    Article  PubMed  CAS  Google Scholar 

  12. Lai CL, Chien RN, Leung NWet al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.N Engl J Med 1998; 339: 61–68.

    Article  PubMed  CAS  Google Scholar 

  13. Heathcote J, Schalm S, Ciancara Jet al. Lamivudine and Intron A combination treatment in chronic hepatitis B infection.Hepatology 1998; 28: S43.

    Google Scholar 

  14. Schiff E, Karayalcin S, Grimm Iet al. A placebo-controlled study of lamivudine and interferon alpha 2 b in patients with chronic hepatitis B who previously failed interferon therapy.Hepatology 1998; 28: S43.

    Google Scholar 

  15. Allen MI, Deslauriers M, Andrews CWet al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.Hepatology 1998; 27: 1670–1677.

    Article  PubMed  CAS  Google Scholar 

  16. Sokal EM, Roberts EA, Mieli-Vergani Get al. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B.Antimicr Agents Chemother 2000; 44: 590–597.

    Article  CAS  Google Scholar 

  17. Lok AS, Ghany MG, Watson G, Ayola B. Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B.J Viral Hepat 1998; 5: 171–178.

    Article  PubMed  CAS  Google Scholar 

  18. Fattovich G, Mclntyre G, Thursz Met al. Hepatitis B virus precore/core variation and interferon therapy.Hepatology 1995; 22: 1355–1362.

    PubMed  CAS  Google Scholar 

  19. Tassopoulos NC, Volpes R, Pastore Get al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B.Lamivudine Precore Mutant Study Group.Hepatology 1999; 29: 889–896.

    Article  PubMed  CAS  Google Scholar 

  20. Ruiz Moreno M, Jimenez J, Porres JC, Bartolome J, Moreno A, Carreno V. A controlled trial of recombinant interferon-alpha in Caucasian children with chronic hepatitis B.Digestion 1990; 45: 26–33.

    PubMed  CAS  Google Scholar 

  21. Ruiz-Moreno M, Rua MJ, Molina Jet al. Prospective, randomized controlled trial of interferon-alpha in children with chronic hepatitis B.Hepatology 1991; 13: 1035–1039.

    PubMed  CAS  Google Scholar 

  22. Utili R, Sagnelli E, Galanti Bet al. Prolonged treatment of children with chronic hepatitis B with recombinant alpha 2a-interferon: a controlled, randomized study.Am J Gastroenterol 1991; 86: 327–330.

    PubMed  CAS  Google Scholar 

  23. Sokal EM, Wirth S, Goyens P, Depreterre A, Cornu C. Interferon alfa-2b therapy in children with chronic hepatitis B.Gut 1993; 34: S87-S90.

    Article  PubMed  CAS  Google Scholar 

  24. Barbera C, Bortolotti F, Crivellaro Cet al. Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B.Hepatology 1994; 20: 287–290.

    Article  PubMed  CAS  Google Scholar 

  25. Sokal EM, Conjeevaram HS, Roberts EAet al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial.Gastroenterology 1998; 114: 988–995.

    Article  PubMed  CAS  Google Scholar 

  26. Kocak N, Saltik IN, Ozen H, Yuce, Gurakan F. Lamivudine treatment for children with interferon refractory chronic hepatitis B.Hepatology 2000; 31: 545.

    Article  PubMed  CAS  Google Scholar 

  27. Kocak N, Ozen H, Saltik IN, Gurakan F, Yuce A. Lamivudine for children with chronic hepatitis B.Am J Gastroenterol 2000; 95: 2989–2990.

    PubMed  CAS  Google Scholar 

  28. Hepatitis C.Wkly Epidemiol Rec 1997; 72: 65–69.

    Google Scholar 

  29. Hepatitis C—global prevalence (update).Wkly Epidemiol Rec 1999; 74 : 425–427.

  30. Chang MH, Ni YH, Hwang LHet al. Long term clinical and virologic outcome of primary hepatitis C virus infection in children: a prospective study.Pediatr Infect Dis J 1994; 13: 769–773.

    Article  PubMed  CAS  Google Scholar 

  31. Vogt M, Lang T, Frosner Get al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening.N Engl J Med 1999; 341: 866–870.

    Article  PubMed  CAS  Google Scholar 

  32. Zancan L, Strafella MS, Brugiolo A, Malusa T, d’Amore ES. Chronic hepatitis C virus infection in childhood and early cirrhosis: it is possible?J Pediatr Gastroenterol Nutr 2000; 30: 350–351.

    Article  PubMed  CAS  Google Scholar 

  33. Ohto H, Terazawa S, Sasaki Net al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group.N Engl J Med 1994; 330: 744–750.

    Article  PubMed  CAS  Google Scholar 

  34. Zanetti AR, Tanzi E, Romano Let al. A prospective study on mother-to-infant transmission of hepatitis C virus.Intervirology 1998; 41: 208–212.

    Article  PubMed  CAS  Google Scholar 

  35. Thomas DL, Villano SA, Riester KAet al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study.J Infect Dis 1998; 177: 1480–1488.

    PubMed  CAS  Google Scholar 

  36. Lin HH, Kao JH, Hsu HYet al. Absence of infection in breastfed infants born to hepatitis C virus-infected mothers.J Pediatr 1995; 126: 589–591.

    Article  PubMed  CAS  Google Scholar 

  37. Legler TJ, Riggert J, Simson Get al. Testing of individual blood donations for HCV RNA reduces the residual risk of transfusion-transmitted HCV infection.Transfusion 2000; 40: 1192–1197.

    Article  PubMed  CAS  Google Scholar 

  38. Beld M, Habibuw MR, Rebers SP, Boom R, Reesink HW. Evaluation of automated RNA-extraction technology and a qualitative HCV assay for sensitivity and detection of HCV RNA in pool-screening systems.Transfusion 2000; 40: 575–579.

    Article  PubMed  CAS  Google Scholar 

  39. Nishiguchi S, Shiomi S, Nakatani Set al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis.Lancet 2001; 357: 196–197.

    Article  PubMed  CAS  Google Scholar 

  40. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirinlor chronic hepatitis C. The Swedish Study Group.Lancet 1998; 351: 83–87.

    Article  PubMed  CAS  Google Scholar 

  41. Poynard T, Marcellin P, Lee SSet al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).Lancet 1998; 352: 1426–1432.

    Article  PubMed  CAS  Google Scholar 

  42. Davis GL, Esteban-Mur R, Rustgi Vet al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.N Engl J Med 1998; 339: 1493–1499.

    Article  PubMed  CAS  Google Scholar 

  43. Reddy KR, Wright TL, Pockros PJet al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.Hepatology 2001; 33: 433–438.

    Article  PubMed  CAS  Google Scholar 

  44. Ruiz-Moreno M, Rua MJ, Castillo Iet al. Treatment of children with chronic hepatitis C with recombinant interferon-alpha: a pilot study.Hepatology 1992; 16: 882–885.

    Article  PubMed  CAS  Google Scholar 

  45. Bortolotti F, Giacchino R, Vajro Pet al. Recombinant interferon-alfa therapy in children with chronic hepatitis C.Hepatology 1995; 22: 1623–1627.

    PubMed  CAS  Google Scholar 

  46. Fujisawa T, Inui A, Ohkawa T, Komatsu H, Miyakawa Y, Onoue M. Response to interferon therapy in children with chronic hepatitis C.J Pediatr 1995; 127: 660–662.

    Article  PubMed  CAS  Google Scholar 

  47. Iorio R, Pensati P, Porzio S, Fariello I, Guida S, Vegnente A. Lymphoblastoid interferon alfa treatment in chronic hepatitis C.Arch Dis Child 1996; 74: 152–156.

    PubMed  CAS  Google Scholar 

  48. Matsuoka S, Mori K, Nakano Oet al. Efficacy of interferons in treating children with chronic hepatitis C.Eur J Pediatr 1997; 156: 704–708.

    Article  PubMed  CAS  Google Scholar 

  49. Jonas MM, Ott MJ, Nelson SP, Badizadegan K, Perez-Atayde AR. Interferon-alpha treatment of chronic hepatitis C virus infection in children.Pediatr Infect Dis J 1998; 17: 241–246.

    Article  PubMed  CAS  Google Scholar 

  50. Sawada A, Tajiri H, Kozaiwa Ket al. Favorable response to lymphoblastoid interferon-alpha in children with chronic hepatitis C.J Hepatol 1998; 28: 184–188.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Viral Hepatitis Research Unit, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University & Hospital, 10330, Bangkok, Thailand

    Voranush Chongsrisawat &  Yong Poovorawan

Authors
  1. Voranush Chongsrisawat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yong Poovorawan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yong Poovorawan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chongsrisawat, V., Poovorawan, Y. Management of chronic hepatitis B and C virus infections. Indian J Pediatr 69, 149–154 (2002). https://doi.org/10.1007/BF02859377

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02859377

Key word

Search

Navigation